Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...

The planned implementation of Medicaid work requirements provides an opportunity to obtain longitudinal data to guide ...

Tobacco use kills more than 7 million people worldwide each year, including 1.3 million who die from the effects of exposure to secondhand smoke.1 As a major contributor to cancer, cardiovascular ...

There is an urgent need for low- and middle-income countries to ensure equitable, affordable, and sustained access to tobacco-cessation medications at scale.

Starting in January 2025, various government health datasets were removed, restored, manipulated, or not posted as planned. The consequences of these changes could be far-reaching.

Nonalcoholic fatty liver disease (NAFLD) is a common condition associated with cirrhosis and hepatocellular carcinoma, affecting approximately 70% of people with obesity or type 2 diabetes. 1 In the ...

Syphilis is one of the oldest known diseases. Approximately 209,000 cases were reported in the United States in 2023 — the highest number of reported cases since 1950 — including nearly 4000 ...

Controversy persists regarding the appropriate duration of therapy with benzathine penicillin G in persons with early (i.e., primary, secondary, or early latent) syphilis (Treponema pallidum infection ...

Venous thromboembolism is a common complication of cancer and its treatments, and the incidence of recurrent thrombosis, serious bleeding, and death is higher among patients with this condition than ...

A 61-year-old woman presented to the emergency department with chest pain. ST-segment elevations were revealed on ECG. A coronary angiogram showed normal coronary arteries, but left ventriculography ...

Patients who have taken opioids for years for chronic pain must be treated differently from those who have not because such therapies cause profound physiological and neurologic changes. Reflexive ...

To the Editor: In the SELECT trial, Lincoff and colleagues (Dec. 14 issue) 1 found that weekly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was superior to placebo in ...